Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 14/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851156 | 0.87 | OPRL1 (0.49) | OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL4858626 | 0.84 | OPRL1 (0.51) | OPRM1OPRL1LMNACYP1A2MEN1 | |
| Citric Acid SCHEMBL4861869 | 0.81 | OPRM1 (0.68) | OPRM1OPRL1KDM4ELMNACYP1A2 | |
| SCHEMBL4858534 | 0.73 | OPRL1 (0.51) | OPRM1OPRL1LMNACYP1A2MEN1 | |
| SCHEMBL4856663 | 0.72 | OPRL1 (0.50) | OPRM1OPRL1LMNACYP1A2MEN1 | |
| SCHEMBL4861071 | 0.72 | OPRM1 (0.67) | OPRM1OPRL1 | |
| SCHEMBL5339483 | 0.72 | OPRL1 (0.48) | OPRM1OPRL1 | |
| SCHEMBL2379652 | 0.71 | OPRM1 (0.69) | OPRM1OPRL1MEN1KMT2APOLB | |
| Citric Acid SCHEMBL5339484 | 0.71 | OPRL1 (0.48) | OPRM1OPRL1KDM4ELMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL302167 | 0.71 | OPRM1 (0.70) | OPRM1OPRL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348354-B2 | Cyclohexylurea compounds | GRUENENTHAL GMBH (DE) | 2008-03-25 | — | — | US | claimed |
| US-20050261358-A1 | antinociceptive agent of opioid-receptor for treating pain; tert-aminecyclohexyl-urea, or -thiourea, or -amide derivatives; 1-(4-dimethylamino-4-phenylcyclohexyl)-3-(3-phenylpropyl)urea hydrochloride; stereoisomers; racemic mixtures | GRUENENTHAL GMBH (DE) | 2005-11-24 | — | — | US | claimed |
| US-7348354-B2 | Cyclohexylurea compounds | GRUENENTHAL GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-20050261358-A1 | antinociceptive agent of opioid-receptor for treating pain; tert-aminecyclohexyl-urea, or -thiourea, or -amide derivatives; 1-(4-dimethylamino-4-phenylcyclohexyl)-3-(3-phenylpropyl)urea hydrochloride; stereoisomers; racemic mixtures | GRUENENTHAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261358-A1 | antinociceptive agent of opioid-receptor for treating pain; tert-aminecyclohexyl-urea, or -thiourea, or -amide derivatives; 1-(4-dimethylamino-4-phenylcyclohexyl)-3-(3-phenylpropyl)urea hydrochloride; stereoisomers; racemic mixtures | OPRL1, OPRM1, OGFRL1 | OPRM1 2/4885OPRL1 1/4885KDM4E 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.